NeoGenomics, Inc. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
NeoGenomics, Inc. (NEO) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 5.54 million shares for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-06.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2021-05-06
- NeoGenomics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2021-03-31 was 5.54M shares.
- NeoGenomics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2020-09-30 was 5.54M shares.
- NeoGenomics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2020-06-30 was 0.00 shares.
- NeoGenomics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2019-09-30 was 0.00 shares.
- NeoGenomics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2020 was 3.72M shares.
- NeoGenomics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2013 was 4.51M shares, a 22.34% increase from fiscal 2012.
- NeoGenomics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2012 was 3.69M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2021-03-31 | 5.54M shares 10-Q · filed 2021-05-06 | ||||||
| 2020-12-31 | 3.72M shares 10-K · filed 2021-02-25 | ||||||
| 2020-09-30 | 5.54M shares 10-Q · filed 2020-10-29 | 0.00 shares 10-Q · filed 2020-10-29 | |||||
| 2020-06-30 | 0.00 shares 10-Q · filed 2020-07-31 | 0.00 shares 10-Q · filed 2020-07-31 | |||||
| 2019-09-30 | 0.00 shares 10-Q · filed 2020-10-29 | 0.00 shares 10-Q · filed 2020-10-29 | |||||
| 2019-06-30 | 0.00 shares 10-Q · filed 2020-07-31 | 0.00 shares 10-Q · filed 2020-07-31 | |||||
| 2014-09-30 | 2.65M shares 10-Q · filed 2014-11-04 | ||||||
| 2014-06-30 | 3.84M shares 10-Q · filed 2014-07-29 | 3.96M shares 10-Q · filed 2014-07-29 | |||||
| 2014-03-31 | 4.19M shares 10-Q · filed 2014-05-12 | ||||||
| 2013-12-31 | 4.51M shares 10-K · filed 2014-02-24 | ||||||
| 2013-09-30 | 4.24M shares 10-Q · filed 2014-11-04 | 4.59M shares 10-Q · filed 2014-11-04 | |||||
| 2013-06-30 | 4.95M shares 10-Q · filed 2014-07-29 | 4.95K shares 10-Q · filed 2013-08-02 | 4.77M shares 10-Q · filed 2014-07-29 | 4.77K shares 10-Q · filed 2013-08-02 | |||
| 2013-03-31 | 4.66M shares 10-Q · filed 2014-05-12 | 4.66K shares 10-Q · filed 2013-05-13 | |||||
| 2012-12-31 | 3.69M shares 10-K · filed 2014-02-24 | 3.69K shares 10-K · filed 2013-02-21 | |||||
| 2012-09-30 | 3.28M shares 10-Q · filed 2013-10-30 | ||||||
| 2012-06-30 | 2.70K shares 10-Q · filed 2013-08-02 | 2.67K shares 10-Q · filed 2013-08-02 | |||||
| 2012-03-31 | 2.73K shares 10-Q · filed 2013-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |